NO20010982L - Fremgangsmåte for å administrere insulinotropiske peptider - Google Patents

Fremgangsmåte for å administrere insulinotropiske peptider

Info

Publication number
NO20010982L
NO20010982L NO20010982A NO20010982A NO20010982L NO 20010982 L NO20010982 L NO 20010982L NO 20010982 A NO20010982 A NO 20010982A NO 20010982 A NO20010982 A NO 20010982A NO 20010982 L NO20010982 L NO 20010982L
Authority
NO
Norway
Prior art keywords
administering
insulinotropic peptides
inhalation
peptide
molecules
Prior art date
Application number
NO20010982A
Other languages
English (en)
Other versions
NO20010982D0 (no
Inventor
Benjamin Lee Hughes
Ronald Keith Wolff
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20010982(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20010982D0 publication Critical patent/NO20010982D0/no
Publication of NO20010982L publication Critical patent/NO20010982L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Oppfinnelsen vedrører en fremgangsmåte for administrering av glukagonlignende peptid-1 molekyler ved inhalering, en fremgangsmåte for å behandle diabetes ved administrering av glykagonlignende peptid-1 molekyler ved inhalering, og en fremgangsmåte for å behandle hyperglycemi ved administrering av glykagon-lignende peptid-1-molekyler ved inhalering.
NO20010982A 1998-08-28 2001-02-27 Fremgangsmåte for å administrere insulinotropiske peptider NO20010982L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9827398P 1998-08-28 1998-08-28
US10001298P 1998-09-11 1998-09-11
PCT/US1999/019348 WO2000012116A1 (en) 1998-08-28 1999-08-24 Method for administering insulinotropic peptides

Publications (2)

Publication Number Publication Date
NO20010982D0 NO20010982D0 (no) 2001-02-27
NO20010982L true NO20010982L (no) 2001-04-27

Family

ID=26794577

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010982A NO20010982L (no) 1998-08-28 2001-02-27 Fremgangsmåte for å administrere insulinotropiske peptider

Country Status (21)

Country Link
EP (1) EP0997151B1 (no)
JP (1) JP2002523466A (no)
KR (1) KR20010073033A (no)
CN (1) CN1314818A (no)
AR (1) AR022368A1 (no)
AT (1) ATE347902T1 (no)
AU (1) AU764371B2 (no)
BR (1) BR9913284A (no)
CA (1) CA2341454A1 (no)
CO (1) CO5090908A1 (no)
CZ (1) CZ2001690A3 (no)
DE (1) DE69934380D1 (no)
EA (1) EA200100289A1 (no)
HR (1) HRP20010141A2 (no)
HU (1) HUP0103369A3 (no)
IL (1) IL141241A0 (no)
NO (1) NO20010982L (no)
PE (1) PE20001031A1 (no)
PL (1) PL346317A1 (no)
TR (1) TR200100600T2 (no)
WO (1) WO2000012116A1 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2001051071A2 (en) * 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US6540983B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
WO2001093837A2 (en) * 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU2002308706A1 (en) * 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2003033671A2 (en) 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
CA2479751C (en) 2002-03-20 2008-06-03 Trent Poole Inhalation apparatus
JP4828940B2 (ja) * 2002-08-01 2011-11-30 マンカインド コーポレイション 細胞輸送組成物およびこれらの使用
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
RU2006120079A (ru) 2003-12-18 2008-01-27 Ново Нордиск А/С (DK) Производные глюкагоноподобного пептида-1 (glp-1)
KR101273120B1 (ko) 2004-08-20 2013-06-13 맨카인드 코포레이션 다이케토피페라진 합성의 촉매 작용
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
KR100704447B1 (ko) * 2005-05-16 2007-04-09 정용현 3단계로 코팅되는 김치 유산균의 코팅방법 및 그로부터 제조된 코팅된 김치유산균 및 코팅된 김치 유산균이 함유된 조성물
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
HUE029798T2 (en) * 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
ES2390286T3 (es) 2005-12-16 2012-11-08 Nektar Therapeutics Conjugados poliméricos de GLP-1
BRPI0707991B8 (pt) 2006-02-22 2021-05-25 Mannkind Corp métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
PE20121528A1 (es) * 2006-09-13 2012-12-12 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
EP2502618A3 (en) * 2007-04-30 2012-10-03 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
PL2211842T3 (pl) * 2007-10-24 2015-12-31 Mannkind Corp Preparat suchego proszku do inhalacji zawierający glp-1 do stosowania w leczeniu hiperglikemii i cukrzycy w podawaniu płucnym
CN104491962B (zh) 2008-06-13 2018-10-23 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
PT2379100E (pt) 2009-01-08 2015-02-09 Mannkind Corp Tratamento de hiperglicemia com glp-1
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8734845B2 (en) 2009-06-12 2014-05-27 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
EP2582421A1 (en) 2010-06-21 2013-04-24 MannKind Corporation Dry powder drug delivery system and methods
SG10201606220QA (en) 2011-04-01 2016-09-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
KR20140095483A (ko) 2011-10-24 2014-08-01 맨카인드 코포레이션 통증을 치료하기 위한 방법 및 조성물
JP6312262B2 (ja) 2012-07-12 2018-04-18 マンカインド コーポレイション 乾燥粉末薬物送達システム
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
SG11201507564PA (en) 2013-03-15 2015-10-29 Mannkind Corp Microcrystalline diketopiperazine compositions and methods
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2018155254A1 (ja) 2017-02-21 2018-08-30 Ｊｆｅスチール株式会社 高炭素熱延鋼板およびその製造方法
GB201917723D0 (en) 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
RU2214419C2 (ru) * 1996-08-30 2003-10-20 Ново Нордиск А/С Glp-1 производные
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU748756B2 (en) * 1997-07-18 2002-06-13 Infimed Therapeutics, Inc. Biodegradable macromers for the controlled release of biologically active substances

Also Published As

Publication number Publication date
CA2341454A1 (en) 2000-03-09
HUP0103369A2 (hu) 2002-02-28
HUP0103369A3 (en) 2002-03-28
HRP20010141A2 (en) 2002-02-28
IL141241A0 (en) 2002-03-10
ATE347902T1 (de) 2007-01-15
EA200100289A1 (ru) 2001-10-22
PL346317A1 (en) 2002-01-28
CZ2001690A3 (cs) 2002-04-17
DE69934380D1 (de) 2007-01-25
EP0997151A3 (en) 2000-09-20
AU5584199A (en) 2000-03-21
CN1314818A (zh) 2001-09-26
AU764371B2 (en) 2003-08-14
WO2000012116A1 (en) 2000-03-09
BR9913284A (pt) 2001-05-15
JP2002523466A (ja) 2002-07-30
KR20010073033A (ko) 2001-07-31
EP0997151A2 (en) 2000-05-03
NO20010982D0 (no) 2001-02-27
PE20001031A1 (es) 2000-10-12
EP0997151B1 (en) 2006-12-13
TR200100600T2 (tr) 2001-07-23
AR022368A1 (es) 2002-09-04
CO5090908A1 (es) 2001-10-30

Similar Documents

Publication Publication Date Title
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
WO2003061362A3 (en) Methods and compositions for treating polycystic ovary syndrome
NO20003051L (no) Metode for administrering av AspB28-humant insulin
DK0733644T3 (da) Glucagonlignende, insulinotrope komplekser, sammensætninger og fremgangsmåder
WO2006024275A3 (de) Erfindung betreffend glp-1 und exendin
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
ZA200606153B (en) Intranasal administration of glucose-regulating peptides
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
DE68929217D1 (en) Insulinotropes hormon
MXPA03007374A (es) Metodos para tratar diabetes mellitus.
NO20015932L (no) Fremgangsmåte til å behandle diabetes
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos
UA88862C2 (en) Glucagon-like peptide-1 analogs

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application